| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | - | 537.585 | 4.689.355 | 5.922.835 | 41.056.905 |
| Total Income - EUR | - | - | - | - | - | - | 537.668 | 5.599.591 | 7.800.483 | 42.381.078 |
| Total Expenses - EUR | - | - | - | - | - | - | 502.734 | 5.300.369 | 7.430.759 | 40.893.233 |
| Gross Profit/Loss - EUR | - | - | - | - | - | - | 34.934 | 299.222 | 369.724 | 1.487.845 |
| Net Profit/Loss - EUR | - | - | - | - | - | - | 29.665 | 85.114 | 193.027 | 1.198.200 |
| Employees | - | - | - | - | - | - | 6 | 24 | 32 | 39 |
Check the financial reports for the company - Gilead Sciences (Gsr) S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | - | 196.782 | 215.646 | 194.098 | 198.317 |
| Current Assets | - | - | - | - | - | - | 1.794.332 | 3.590.923 | 8.569.223 | 57.393.426 |
| Inventories | - | - | - | - | - | - | 0 | 0 | 325.694 | 9.428.128 |
| Receivables | - | - | - | - | - | - | 553.061 | 2.360.593 | 3.769.623 | 40.179.763 |
| Cash | - | - | - | - | - | - | 1.241.271 | 1.230.330 | 4.473.906 | 7.785.536 |
| Shareholders Funds | - | - | - | - | - | - | 587.105 | 674.040 | 865.023 | 2.058.389 |
| Social Capital | - | - | - | - | - | - | 557.439 | 559.169 | 557.473 | 554.357 |
| Debts | - | - | - | - | - | - | 1.404.010 | 3.152.655 | 7.912.287 | 55.542.442 |
| Income in Advance | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Gilead Sciences (Gsr) S.r.l.